Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif., May 15, 2024 PALO...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio...
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results PR Newswire PALO ALTO, Calif., March...
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 PR...
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and...
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif., Jan. 4, 2024 PALO ALTO, Calif...
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference PR Newswire PALO ALTO, Calif., Nov. 21, 2023 PALO ALTO, Calif...
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights PR Newswire PALO ALTO, Calif., Nov. 14, 2023 PALO...
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following...
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC...
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society PR Newswire PALO ALTO, Calif., Oct...
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire PALO ALTO, Calif., Sept. 8, 2023 PALO ALTO...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads